Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Company to conduct 1x1 meetings on April 24, 2025
GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion.
Dr. Dritschilo's presentation will focus on providing an overview and update on the Company's ongoing Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma as well as advancements being made in the Company's Shuttle Diagnostics subsidiary which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients.
To access the live presentation, please use the following information:
Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub
Date: Wednesday, April 23, 2025
Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NV
Webcast: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/Js2DcQMoTdPkzijmn5bhuj
If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at 1x1@lythampartners.com. 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle PharmaceuticalsAnatoly Dritschilo, M.D.Chairman and Chief Scientific Officer240-403-4212info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert Blum602-889-9700shph@lythampartners.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
21 minutes ago
- Business Wire
Securities Fraud Investigation Into Neogen Corporation (NEOG) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz continues its investigation of Neogen Corporation ('Neogen' or the 'Company') (NASDAQ: NEOG) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEOGEN CORPORATION (NEOG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 4, 2025, Neogen disclosed that, while its fourth quarter fiscal 2025 financial results would be 'materially approximate [to] where [the Company] had put [its] guide,' it 'would expect EBITDA margin to probably be around the high-teens' compared to the previous quarter's 22%. The Company explained that EBITDA margins would likely 'be in the low-20s, if not for the elevated inventory write-offs.' On this news, Neogen's stock price fell $1.04, or 17.3%, to close at $4.96 per share on June 4, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Neogen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
23 minutes ago
- Yahoo
Informa TechTarget and Salesloft Announce Strategic Partnership to Help Customers Grow Revenue Through Precise, Data-Driven Prospecting
Together, the companies help sellers engage with active buying groups showing demonstrated interest in and genuine need for their solutions. NEWTON, Mass. & ATLANTA, June 23, 2025--(BUSINESS WIRE)--TechTarget, Inc. ("Informa TechTarget") (Nasdaq: TTGT), global growth accelerator and leading provider of intent data and insights to the B2B technology sector, and Salesloft, a leading Revenue Orchestration Platform that helps B2B organizations drive durable revenue growth, today announced a partnership and integration designed to help mutual customers build and accelerate pipeline by efficiently identifying and effectively engaging prospects in an active buying journey. "While 85% of BDRs are laser-focused on outbound prospecting, many of them waste precious cycles pursuing cold contacts who aren't ready to buy. We help reps hit their pipeline targets by identifying buyers who are actively researching relevant solutions through their membership to our trusted editorial communities," said Jillian Coffin, Senior Vice President of Customer Enablement and Strategy, Informa TechTarget. "By automatically delivering these active, permissioned contacts into topically aligned Salesloft cadences, we help sellers engage the right people with the right message at the right time so they can convert more interest into opportunity." The new integration empowers sales teams to: Streamline workflows between Informa TechTarget and Salesloft to maximize sales efficiency Easily add Active Prospects from Informa TechTarget's Priority Engine intent data platform directly into relevant Salesloft cadences in seconds Automatically push Active Prospects to topically aligned Salesloft cadences each week "The combination of Informa TechTarget's active, permissioned contacts with Salesloft's engagement capabilities gives sales teams a meaningful advantage," said Lesley Renna, SVP of Alliances and Ecosystem at Salesloft. "This integration helps our joint customers drive higher productivity and conversion rates by automatically adding prospects in an active buying cycle to Salesloft Cadences tailored to the topics that matter most to them." Key benefits of this strategic partnership include: Precision targeting: Customers can leverage Informa TechTarget's person-level intent data to confidently focus sellers on in-market buyers and buying groups in their territory or ABM targets. Accelerated engagement: Informa TechTarget constantly monitors for new individuals beginning their research journey and automatically delivers these permissioned buyers to Salesloft, drastically reducing the time between intent signals and sales outreach. Higher conversion: With Informa TechTarget, sellers get visibility into the needs, pain points, and current topics of interest for each individual buyer so they can better personalize across every touchpoint, which helps them book more meetings and have meaningful conversations that convert. "The Add to SEP feature integration between Priority Engine and Salesloft is impressively intuitive. I love how new additions appear right at the top in Salesloft," said Theresa Woodiel, Director, ABM & Integrated Marketing at Deep Instinct. "The seamless workflow means our reps can instantly see and engage with their newest priority contacts. It's exactly the kind of straightforward, efficient solution our team needs." The Informa TechTarget-Salesloft integration is available now to current Priority Engine Sales subscribers at no additional cost. Customers must have both a Priority Engine Sales subscription and a Salesloft license to utilize the integration. To learn more, click here. About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. About Salesloft Salesloft powers durable revenue growth for the world's most demanding companies. Salesloft's industry-leading Revenue Orchestration Platform uses purpose-built AI to help market-facing teams prioritize and take action on what matters most, from first touch to upsell and renewal. More than 5,000 customers including Google, 3M, IBM, Shopify, Square, and Cisco gain a performance force multiplier with Salesloft by shifting to a durable revenue engagement model, helping them solve the complexities of modern B2B sales and unlock revenue efficiency. © 2025 TechTarget, Inc d/b/a Informa TechTarget. All rights reserved. All trademarks are the property of their respective owners. View source version on Contacts Garrett MannVP of Corporate CommunicationsInforma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Steve Jobs Once Cited Leonardo Da Vinci's Example To Explain Why All 'Major' Thinkers Had This Trait That Made Them Exceptional
Steve Jobs once argued the greatest innovators are "both the thinker and doer in one person," invoking Leonardo da Vinci to prove that creativity and execution rarely succeed apart. What Happened: Addressing engineers in the early 1990s, the Apple (NASDAQ:APPL) co-founder said, "The doers are the major thinkers. ... Did Leonardo have a guy off to the side thinking five years out what he would paint? Of course not. Leonardo was the artist, but he also mixed all his own paints." Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Jobs's point is that discovery flows from hands-on mastery. "It's very easy to take credit for thinking," he said. "Dig a little deeper and you find the people who really did it were also the people that worked through the hard intellectual problems as well."Veteran biographers note Jobs often cited Renaissance polymaths to justify Apple's marriage of hardware, software and It Matters: The thinker-doer thesis now frames a broader debate over when entrepreneurs hit their stride. Census Bureau data show founders aged 40-plus are likelier to build high-growth firms than their twenty-something peers, a pattern echoed by late-blooming icons such as Ray Kroc at McDonald's Corp. (NYSE:MCD) and Sam Walton at Walmart Inc. (NYSE:WMT). The gap reflects years spent 'doing,' honing skills and spotting problems first-hand before leaping to 'think' up solutions. Modern CEOs frequently echo Jobs. Tesla Inc.'s (NASDAQ:TSLA) Elon Musk reposted the quote last year with a one-word endorsement: "True." Venture capitalist Paul Graham tells founders to "learn by building" because abstract ideation rarely survives first contact with users. For Jobs, that convergence of art and engineering remained Apple's guiding doctrine until his 2011 death. "There is no difference in our industry," he said. "The people that have really made the contributions have been the thinkers and the doers." Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends Photo Courtesy: rnkadsgn on Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Steve Jobs Once Cited Leonardo Da Vinci's Example To Explain Why All 'Major' Thinkers Had This Trait That Made Them Exceptional originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
